These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8973608)

  • 21. AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies.
    Perfetti V; Bellotti V; Garini P; Zorzoli I; Rovati B; Marinone MG; Ippoliti G; Merlini G
    Lab Invest; 1994 Dec; 71(6):853-61. PubMed ID: 7807967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
    Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
    Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
    Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
    PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.
    Steplewski Z; Sun LK; Shearman CW; Ghrayeb J; Daddona P; Koprowski H
    Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4852-6. PubMed ID: 3387441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synovial tissue responses following treatment of rheumatoid arthritis with the humanized monoclonal antibody CAMPATH-1H.
    Soriano ER; Dixey J; Hall ND; Davies J; Maddison PJ
    Arthritis Rheum; 1996 Jan; 39(1):181-2. PubMed ID: 8546734
    [No Abstract]   [Full Text] [Related]  

  • 30. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
    Jones JL; Phuah CL; Cox AL; Thompson SA; Ban M; Shawcross J; Walton A; Sawcer SJ; Compston A; Coles AJ
    J Clin Invest; 2009 Jul; 119(7):2052-61. PubMed ID: 19546505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
    Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
    Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.
    Buchsbaum DJ; Brubaker PG; Hanna DE; Glatfelter AA; Terry VH; Guilbault DM; Steplewski Z
    Cancer Res; 1990 Feb; 50(3 Suppl):993s-999s. PubMed ID: 2297753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.
    Isaacs JD; Burrows N; Wing M; Keogan MT; Rebello PR; Watts RA; Pye RJ; Norris P; Hazelman BL; Hale G; Waldmann H
    Clin Exp Immunol; 1997 Nov; 110(2):158-66. PubMed ID: 9367397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.
    Alakhras NS; Qiu J; Rocha GV; Witcher DR; Koester A; You J; Schaer DA; Holmgaard RB; Driscoll K; Willy JA; Malherbe LP
    MAbs; 2018; 10(6):913-921. PubMed ID: 29953319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies.
    Guyre CA; Gomes D; Smith KA; Kaplan JM; Perricone MA
    J Immunol Methods; 2008 Apr; 333(1-2):51-60. PubMed ID: 18314132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.
    Cox AL; Thompson SA; Jones JL; Robertson VH; Hale G; Waldmann H; Compston DA; Coles AJ
    Eur J Immunol; 2005 Nov; 35(11):3332-42. PubMed ID: 16231285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation.
    Piccaluga PP; Martinelli G; Malagola M; Rondoni M; Bianchini M; Vigna E; Bosi C; Gaitani S; Visani G; Baccarani M
    Leuk Lymphoma; 2004 Apr; 45(4):731-3. PubMed ID: 15160947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
    Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.